Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma

Mayo ClinicSmall moleculePhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

0 Active assets in the Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
Veliparib
National Cancer Institute (NCI)
Phase 1/2CCC
Vinorelbine
National Cancer Institute (NCI)
Phase 1/2CCC
Yttrium Y 90 Basiliximab
City of Hope Medical Center
Phase 1CC
Dasatinib
National Cancer Institute (NCI)
Phase 1CC
Cytosin-Arabinosid
City of Hope Medical Center
Phase 1CC

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →